2002
ZD1839 (Iressa™) in Non-Small Cell Lung Cancer
Herbst RS, Kies MS. ZD1839 (Iressa™) in Non-Small Cell Lung Cancer. The Oncologist 2002, 7: 9-15. PMID: 12202783, DOI: 10.1634/theoncologist.7-suppl_4-9.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorLung cancerAdvanced non-small cell lung cancerEGFR tyrosine kinase inhibitor ZD1839Treatment of NSCLCCisplatin-based combination chemotherapyAnti-EGFR agentsConventional cytotoxic chemotherapyAvailable clinical dataGrowth factor receptorCombination chemotherapyCytotoxic chemotherapyPatient populationClinical dataClinical developmentGreater efficacyFactor receptorZD1839Less toxicityUseful targetChemotherapyCancerPrognosisPharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro J, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson R, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Journal Of Clinical Oncology 2002, 20: 110-24. PMID: 11773160, DOI: 10.1200/jco.2002.20.1.110.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntineoplastic AgentsApoptosisBiomarkersCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p27Dose-Response Relationship, DrugErbB ReceptorsFemaleGefitinibHumansKeratinocytesMaleMAP Kinase Signaling SystemMiddle AgedNeoplasmsQuinazolinesSkinStatistics, NonparametricTumor Suppressor ProteinsConceptsCancer patientsEpidermal growth factor receptor tyrosine kinase inhibitor ZD1839Tyrosine kinase inhibitor ZD1839Phase I clinical trialMaximum-tolerated doseDose-limiting toxicityEGFR activationReceptor-dependent processUnacceptable toxicityDefinitive efficacyPharmacodynamic assessmentSafety trialPharmacodynamic effectsClinical trialsKeratin plugsReceptor inhibitionMaturation markersSkin biopsiesPharmacodynamic studiesProliferation indexDose levelsOral ZD1839PatientsOptimal dosesZD1839
2001
ZD1839 (Iressa™) In Non–Small-Cell Lung Cancer
Herbst R, Khuri F, Fossella F, Glisson B, Kies M, Pisters K, Riddle J, Terry K, Lee J. ZD1839 (Iressa™) In Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2001, 3: 27-32. PMID: 14656386, DOI: 10.3816/clc.2001.n.014.Peer-Reviewed Original ResearchEpidermal growth factor receptorCell lung cancerAdvanced diseaseLung cancerPhase III clinical developmentEGFR tyrosine kinase inhibitorsAcceptable tolerability profileSelective EGFR tyrosine kinase inhibitorNSCLC cell linesTumor cell growthGrowth factor receptorAdvanced NSCLCTolerability profileNSCLC patientsPoor prognosisClinical activityMetastatic spreadInhibition of apoptosisPreclinical studiesHuman xenograftsClinical developmentTumor typesGrowth delayTumor progressionZD1839Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition
Albanell J, Rojo F, Averbuch S, Feyereislova A, Herbst R, LoRusso P, Rischin D, Gee J, Nicholson R, Baselga J. Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition. European Journal Of Cancer 2001, 37: s159. DOI: 10.1016/s0959-8049(01)81071-6.Peer-Reviewed Original Research
2000
Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
Kris M, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, Feyereislova A, Ochs J, Averbuch S. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 2000, 29: 72. DOI: 10.1016/s0169-5002(00)80233-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorNon-small cell lung cancer patientsCell lung cancer patientsPhase I trialSelective tyrosine kinase inhibitorLung cancer patientsTyrosine kinase inhibitorsGrowth factor receptorObjective regressionI trialCancer patientsOral ZD1839Kinase inhibitorsFactor receptorPatientsZD1839